Personalized Melanoma Vaccine Shows Promise in Clinical Trials

A personalized melanoma vaccine, intismeran, developed by Moderna and Merck, is showing promising results in clinical trials. The treatment involves up to nine doses of the vaccine, administered every three weeks, following surgical removal of the tumor. It is used in combination with Keytruda, an immunotherapy drug, for approximately one year.

A Phase 3 clinical study involving 1,137 patients with stage IIB-IV melanoma found that the combination therapy reduced the risk of the cancer returning or spreading compared to patients receiving Keytruda alone. Researchers are continuing to monitor the long-term benefits of this treatment.

Melanoma, the most aggressive form of skin cancer, causes about 2,600 deaths annually in the UK. For the most severe cases, survival rates are low, with roughly one-third of patients living at least five years post-diagnosis.

The intismeran vaccine is not a one-size-fits-all treatment. It is designed based on the unique genetic makeup of each patient's tumor. After tumor removal, a sample is analyzed to identify specific mutations in cancer cells that produce neoantigens. These are specific elements that the immune system can recognize. Messenger RNA (mRNA) technology is then used to create a personalized vaccine that can include information for up to 34 neoantigens.

The vaccine's goal is to enhance the immune system's ability to detect cancer cells displaying these patient-specific tumor characteristics. Once administered, the body's cells use the mRNA instructions to temporarily produce proteins corresponding to the selected neoantigens, thereby alerting the immune system.